CMS Open Payments · Program Year 2024
Takeda Pharmaceuticals U.S.A., Inc.
Takeda Pharmaceuticals U.S.A., Inc. reported $199,919,045.16 in payments to 172,058 physicians and teaching hospitals across 186,599 transactions.
- $199.9M
- Total payments
- 186,599
- Transactions
- 172,058
- Recipients
- +$17.3M
- General Payments vs PY2023
Takeda Pharmaceuticals U.S.A., Inc. reported $199,919,045.16 in payments to 172,058 physicians and teaching hospitals in CMS Open Payments Program Year 2024 - ranking #15 of 1,925 reporting manufacturers (1.4% of all US industry payments), averaging $1.2K per recipient across 9 payment categories. Figures are company-reported under the Physician Payments Sunshine Act; a reported payment is a financial relationship, not evidence of wrongdoing.
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
The verdict
Takeda Pharmaceuticals U.S.A., Inc. pairs top-1% payment volume with a moderately concentrated payment pattern.
- #15
- of 1,925 companies
- 1.4%
- of all US industry payments
- 0.4%
- paid to its single top recipient
- 9
- payment categories
Release-over-release change
General Payments changed from PY2023 to PY2024
Takeda Pharmaceuticals U.S.A., Inc.'s CMS-reported General Payments increased by $17.3M (+31.2%) from PY2023 to PY2024. The comparison uses the same CMS manufacturer-by-payment-category summary for both years and excludes research and ownership or investment records.
CMS source labels for this exact identifier: PY2022: TAKEDA PHARMACEUTICALS U.S.A., INC.PY2023: TAKEDA PHARMACEUTICALS U.S.A., INC.PY2024: Takeda Pharmaceuticals U.S.A., Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $55,483,057.02
- PY2024
- $72,798,431.97
How Takeda Pharmaceuticals U.S.A., Inc. ranks nationally
Where this company's total reported payments fall within the full national distribution of all 1,925 companies in CMS Open Payments, not just its nearest peers.
Takeda Pharmaceuticals U.S.A., Inc.'s total vs. every reporting company
CMS Open Payments, Program Year 2024
$199,919,045 Top 1% higher than 99% of 1,925 reporting companies
Each bar is a progressively wider band; taller bars hold more reporting companies. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source CMS Open Payments · 2024
What the Data Shows for Takeda Pharmaceuticals U.S.A., Inc.
Averaging $1.1K per transaction and $1.2K per recipient, Takeda Pharmaceuticals U.S.A., Inc.'s Program Year 2024 total comes to $199,919,045.16 across 186,599 transactions and 172,058 physicians and teaching hospitals. In the CMS Open Payments database that is good for rank #15 of 1,925 companies, a top-tier 1.4% share of all industry payments reported nationwide for the year.
"Royalty or License" leads the 9-category general-payment breakdown below at $44.5M (22.3% of the company's reported total, 27 transactions) - see our methodology for how research and ownership payments are reported separately.
General Payment Breakdown by Type
Across 9 types of general payments, Takeda Pharmaceuticals U.S.A., Inc.'s largest category was "Royalty or License" at $44.5M - 22.3% of the company's reported total.
How Takeda Pharmaceuticals U.S.A., Inc. divides its payments
How the reported total splits across payment categories
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Royalty or License | $44.5M | 27 | 22.3% |
| Consulting Fee | $10.5M | 4,087 | 5.3% |
| Compensation for Services Other Than Consulting | $6.3M | 985 | 3.2% |
| Space Rental or Facility Fees | $3.6M | 469 | 1.8% |
| Food and Beverage | $3.5M | 162,392 | 1.8% |
| Grant | $2.0M | 27 | 1.0% |
| Travel and Lodging | $1.1M | 2,754 | 0.6% |
| Education | $654.4K | 1,310 | 0.3% |
| Charitable Contribution | $499.3K | 7 | 0.2% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $44,946,140.80 (61.7%) of $72,798,431.97 in this company's General Payments records across 52,038 recipients. This is a CMS Open Payments Program Year 2024 General Payments view only: it excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Takeda Pharmaceuticals U.S.A., Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Massachusetts General Hospital
$27,230,462.12 across 6 reported transactions
- 2
Childrens Hospital Corporation
$10,099,059.07 across 15 reported transactions
- 3
Univ of Mi Hospitals & Hlth Ctrs
$4,680,763.63 across 18 reported transactions
- 4
Emory University Hospital
$1,675,055.98 across 8 reported transactions
- 5
Cleveland Clinic Hospital
$1,260,800.00 across 32 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Payment Size Analysis
Average transaction size: $1.1K. Average per recipient: $1.2K.
Total Amount
$199,919,045.16
Avg per Transaction
$1.1K
Avg per Recipient
$1.2K
Payment Transparency Context
What is the Sunshine Act?
The Physician Payments Sunshine Act (part of the Affordable Care Act) requires pharmaceutical and medical device manufacturers to report payments and transfers of value to physicians and teaching hospitals. These payments can include consulting fees, research grants, speaker fees, food and beverages, travel, royalties, and other forms of compensation.
Industry Total (2024)
$13.9B
across 1,925 companies
Takeda Pharmaceuticals U.S.A., Inc. Share
1.4%
#15 by total payments
Companies with Similar Payment Volumes
Pharmaceutical companies with payment totals similar to Takeda Pharmaceuticals U.S.A., Inc.
Frequently Asked Questions
How much did Takeda Pharmaceuticals U.S.A., Inc. pay to physicians and hospitals in 2024? ▾
How many physicians received payments from Takeda Pharmaceuticals U.S.A., Inc.? ▾
What types of payments did Takeda Pharmaceuticals U.S.A., Inc. make? ▾
How does Takeda Pharmaceuticals U.S.A., Inc. rank among pharmaceutical companies? ▾
What is the average payment size from Takeda Pharmaceuticals U.S.A., Inc.? ▾
Where does the payment data for Takeda Pharmaceuticals U.S.A., Inc. come from? ▾
Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-25.